- Home
- SUZ vs JAZZ Comparison
SUZ vs JAZZ Comparison
Compare SUZ & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUZ | JAZZ |
|---|---|---|
| Founded | 1924 | 2003 |
| Country | Brazil | Ireland |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.4B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | SUZ | JAZZ |
|---|---|---|
| Price | $8.36 | $237.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $217.57 |
| AVG Volume (30 Days) | ★ 2.8M | 792.0K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $13.28 | $6.22 |
| Revenue Next Year | $13.57 | $7.68 |
| P/E Ratio | ★ $5.58 | $53.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.11 | $105.00 |
| 52 Week High | $11.54 | $243.32 |
Technical Indicators
Market Signals| Indicator | SUZ | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 72.67 |
| Support Level | $8.11 | $159.78 |
| Resistance Level | $9.66 | N/A |
| Average True Range (ATR) | 0.19 | 5.85 |
| MACD | 0.01 | 0.18 |
| Stochastic Oscillator | 27.11 | 75.37 |
Price Performance
Historical ComparisonAbout SUZ Suzano S.A.
Suzano SA produces and sells pulp and a variety of paper products. The company organizes itself into two segments based on product type: Pulp and Paper. The Pulp segment generates the majority of revenue. The firm's product portfolio includes printing and writing paper, paperboard, diapers, and sanitary napkins. The company owns forest land and plants in Brazil, where it harvests timber and turns the timber into pulp and paper in its plants.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.